• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncometabolites from TCA Cycle Influence Cancer Immunity

Bioengineer by Bioengineer
September 10, 2025
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

With the emergence of research surrounding cancer metabolism, the role of oncometabolites derived from the tricarboxylic acid (TCA) cycle has garnered considerable interest. As detailed in a recent study led by Sarkar et al., these metabolites play a crucial role in altering both tumor behavior and the surrounding immune microenvironment. The researchers reveal how the disruption of normal metabolic pathways leads to the accumulation of these harmful byproducts, which not only fuel tumor growth but also manipulate immune responses within the tumor niche.

The TCA cycle is a central metabolic pathway that plays a pivotal role in cellular respiration and energy production. However, cancer cells often exhibit altered metabolism, referred to as the Warburg effect, where they rely more on glycolysis for energy production, even in the presence of oxygen. This metabolic shift results in the production of various oncometabolites that can have significant implications for tumor growth and metastasis.

One of the primary oncometabolites discussed in the research is 2-hydroxyglutarate (2-HG), which has gained recognition for its role in driving tumorigenesis in specific types of malignancies, particularly gliomas and acute myeloid leukemia. The study elucidates how the accumulation of 2-HG occurs via mutations in isocitrate dehydrogenase (IDH) enzymes, which leads to profound epigenetic changes and altered transcriptional programs in tumor cells.

Additionally, fumarate and succinate are other notable oncometabolites derived from TCA cycle dysregulation. The research emphasizes how succinate accumulation, primarily associated with hereditary cancer syndromes such as fumarate hydratase deficiency, can reactivate hypoxia-inducible factor (HIF) pathways. This reactivation results in increased angiogenesis and a pro-tumorigenic environment, creating a perfect storm for tumor progression.

As the immune landscape is intricately linked to tumor metabolism, the study makes a compelling case for examining how these oncometabolites influence immune cell function. Whereas traditional views have largely separated cancer biology and immunology, current findings illustrate a much more complex interaction. For instance, elevated levels of certain metabolites can inhibit T cell activation, thus providing tumors with a means of evading immune surveillance.

The implications of altered TCA cycle metabolism extend beyond mere tumor growth. The research showcases how the interplay between oncometabolites and immune cells can dictate therapeutic outcomes. Understanding the metabolic cross-talk in the tumor microenvironment presents new avenues for immunotherapy. The study argues that if we can manipulate these metabolic pathways, it may be possible to enhance the efficacy of existing treatments or even develop novel strategies targeting metabolic vulnerabilities in tumors.

The authors further discuss the emerging therapeutic potential of targeting these oncometabolites in cancer treatment. Inhibitors that specifically target metabolic pathways associated with oncometabolite production are currently in preclinical and clinical development. For instance, IDH inhibitors have shown promise in treating patients with IDH-mutant cancers, effectively reducing 2-HG levels and thereby reverting some of the malignant features induced by the metabolite.

Moreover, the study emphasizes the importance of combining metabolic therapies with immunotherapies, suggesting that a dual-targeted approach may yield synergistic effects. Recent clinical trials have begun to explore this combination, as fostering a more favorable immune environment while simultaneously crippling the tumor’s energetic capabilities could lead to enhanced therapeutic responses.

In addition to pointing toward novel treatment strategies, the insights gleaned from the study encourage a broader reevaluation of cancer metabolism as a critical factor influencing tumor biology. Researchers are now urged to integrate metabolic profiling into routine clinical practice, as it may not only serve as a prognostic biomarker but also inform treatment decisions based on the distinct metabolic vulnerabilities of individual tumors.

As cancer biology continues to evolve, the understanding of TCA cycle-derived oncometabolites will undoubtedly shape future research directions. The intricate relationship between metabolism and immune response underscores a fundamental shift in how cancer is perceived and treated. It’s a clarion call for researchers and clinicians alike to forge new paths that bridge these two critical fields.

The study by Sarkar and colleagues represents a significant contribution to our understanding of cancer metabolism and the immune microenvironment. As awareness grows, the acknowledgment of these metabolic mechanisms may catalyze the development of innovative therapeutic strategies aimed at dismantling the metabolic foundations of cancer. In the coming years, the promise of exploiting oncometabolites for therapeutic gain will likely become more apparent, ushering in a new era of precision oncology.

The exploration of TCA cycle-derived oncometabolites epitomizes the intertwined nature of cancer progression and the immune response, urging a shift in focus towards a combined metabolic and immunological approach in tackling cancer. As the scientific community continues to unravel the complexities of tumor metabolism, it is clear that the road ahead holds great potential for discovering effective and targeted interventions that could transform cancer care for patients around the globe.

Subject of Research: TCA cycle-derived oncometabolites in cancer and the immune microenvironment

Article Title: TCA cycle-derived oncometabolites in cancer and the immune microenvironment

Article References:

Sarkar, S., Chang, CI., Jean, J. et al. TCA cycle-derived oncometabolites in cancer and the immune microenvironment.
J Biomed Sci 32, 87 (2025). https://doi.org/10.1186/s12929-025-01186-y

Image Credits: AI Generated

DOI: 10.1186/s12929-025-01186-y

Keywords: TCA cycle, oncometabolites, cancer metabolism, immune microenvironment, 2-hydroxyglutarate, fumarate, succinate, immunotherapy, metabolic therapy.

Tags: 2-hydroxyglutarate tumorigenesisaltered metabolism in cancer cellscancer metabolism researchgliomas and acute myeloid leukemiaIDH mutations and cancerimmune microenvironment in tumorsmetabolic pathways in cancermetabolic shifts in tumor cellsoncometabolites in cancerTCA cycle and cancer immunitytumor behavior and immune responsesWarburg effect and tumor growth

Tags: cancer immune microenvironmentIDH mutations cancer epigeneticsmetabolic immunotherapy synergyoncometabolites tumor immune evasionTCA cycle oncometabolites
Share12Tweet8Share2ShareShareShare2

Related Posts

Examining Patients’ Financial Strain at Hospital Clinics

October 23, 2025

Internet Use and Loneliness in China’s Seniors

October 23, 2025

High-Fat Winter Snacks Could Mislead the Body Into Gaining Weight

October 23, 2025

Cellarity Unveils New Framework for Discovering Cell State-Correcting Medicines in Science

October 23, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1277 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    165 shares
    Share 66 Tweet 41
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Examining Patients’ Financial Strain at Hospital Clinics

Internet Use and Loneliness in China’s Seniors

High-Fat Winter Snacks Could Mislead the Body Into Gaining Weight

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.